Skip to content
Home
Kevin M. Biglan, M.D., M.P.H.

Kevin M. Biglan, M.D., M.P.H.

Contact

Appointment (585) 341-7500
Fax (585) 276-1870
Administrative (585) 275-7430

About Me

Telemedicine: (585) 275-7430
Dr. Kevin Biglan is a Professor of Neurology and the Associate Chair for Clinical Research in the Department of Neurology and the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry in Rochester, New York. He als...
Telemedicine: (585) 275-7430
Dr. Kevin Biglan is a Professor of Neurology and the Associate Chair for Clinical Research in the Department of Neurology and the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry in Rochester, New York. He also serves as Director of the National Parkinson Foundation Center of Excellence and Director of the Huntington Disease Society of America Center of Excellence at the University of Rochester. He is fellowship trained in movement disorders and provides comprehensive services to individuals with Parkinson's disease, Huntington's disease, tremor, dystonia and other movement disorders. He also provides botulinum toxin injections for the treatment of dystonia and related conditions.
Dr. Biglan has been actively involved in the development of telemedicine for the provision of care in patients with Parkinson disease and for identifying disease modifying therapy in Parkinson's disease and Huntington's disease. He has been at the forefront of establishing the feasibility of telemedicine in Parkinson disease and Huntington disease, the expansion of its use for clinical care, and the validation of clinical trial outcomes assessed via telemedicine. He conducts weekly movement disorders clinics via telemedicine at various spoke sites throughout New York.

Faculty Appointments

Clinical Professor (Voluntary) - Department of Neurology, Movement Disorders (SMD)

Clinical Professor (Voluntary) - Center for Health and Technology - Joint

Credentials

Education

MPH | University of Rochester. Clinical Investigation. 2004

MD | Jefferson Medical College. Medicine. 1996

BS | Albright College. Biology. 1992

Awards

1988-1992 Walton Academic Scholar, Scholarship awarded to the top 10% of matriculating students
1991, 1992 Deans Achievement Award, Award given to junior and senior students for academic excellence
1992 Cyrus E. Beekey Memorial Award, Award to a graduating senior for excellence in biology.
1996 Arthur Krieger Memorial Prize in Neurology, Award to the senior medical student exhibiting excellence in neurology
2000 Alpha Omega Alpha, Medical honor society.
2000 American Academy of Neurology Resident Scholarship, Scholarship awarded to residents exhibiting dedication to teaching
2002,2004 NIH Clinical Research Loan Repayment Award, A competitive award for clinical researchers wishing to pursue a career in academic medicine

Research

Dr. Biglan is actively involved in clinical trials aimed at identifying therapies that slow progression of Parkinson disease and Huntington disease and in designing trials and identifying therapies aimed at delaying onset of disease in Huntington disease. He has served as the PI/co-PI, Steering Comm...
Dr. Biglan is actively involved in clinical trials aimed at identifying therapies that slow progression of Parkinson disease and Huntington disease and in designing trials and identifying therapies aimed at delaying onset of disease in Huntington disease. He has served as the PI/co-PI, Steering Committee member or Medical Monitor on over 13 clinical trials. He was the co-PI on the design and successful conduct of the NINDS funded Phase 2 study of Coenzyme Q10 in premanifest Huntington's disease (PREQUEL) and the Phase 2 study of isradipine in early Parkinson disease (STEADY-PD) and is currently the PI of an NINDS sponsored Phase 3 clinical trial of isradipine in Parkinson's disease (STEADY-PDIII).
Dr. Biglan's current research interests focus on identifying clinical phenotypes in pre-manifest Huntington's disease, identifying disease modifying therapies in Huntington's disease and Parkinson's disease and enhancing the delivery of care to patients with chronic neurodegenerative disorders.

Publications

Journal Articles

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.

Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W

Telemedicine journal and e-health : the official journal of the American Telemedicine Association.. 2016 July 22 (7):590-8. Epub 02/17/2016.

A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders.

Abdolahi A, Bull MT, Darwin KC, Venkataraman V, Grana MJ, Dorsey ER, Biglan KM

Health informatics journal.. 2016 June 22 (2):304-11. Epub 11/11/2014.

Erratum To: Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.

Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER

Trials.. 2016 January 517 :7. Epub 01/05/2016.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C

JAMA neurology.. 2016 January 73 (1):102-10. Epub 1900 01 01.

Telemedicine Care for Nursing Home Residents with Parkinsonism.

Schneider R, Dorsey ER, Biglan K

Journal of the American Geriatrics Society.. 2016 January 64 (1):218-20. Epub 1900 01 01.

Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study.

Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, Dorsey ER, Little MA

Parkinsonism & related disorders.. 2015 June 21 (6):650-3. Epub 03/07/2015.

Feasibility of Virtual Research Visits in Fox Trial Finder.

Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, Biemiller RA, Biglan KM

Journal of Parkinson's disease.. 2015 5 (3):505-15. Epub 1900 01 01.

Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease.

Beglinger LJ, Adams WH, Fiedorowicz JG, Duff K, Langbehn D, Biglan K, Caviness J, Olson B, Paulsen JS

Journal of Huntington's disease.. 2015 4 (3):251-60. Epub 1900 01 01.

Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.

Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER

Trials.. 2014 November 2715 :465. Epub 11/27/2014.

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

Killoran A, Biglan KM

Movement disorders : official journal of the Movement Disorder Society.. 2014 September 1529 (11):1404-13. Epub 08/27/2014.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM,

JAMA neurology.. 2014 June 71 (6):710-6. Epub 1900 01 01.

The past, present, and future of telemedicine for Parkinson's disease.

Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Dorsey ER, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR,

Movement disorders : official journal of the Movement Disorder Society.. 2014 June 29 (7):871-83. Epub 05/17/2014.

Virtual visits for Parkinson disease: A case series.

Venkataraman V, Donohue SJ, Biglan KM, Wicks P, Dorsey ER

Neurology. Clinical practice.. 2014 April 4 (2):146-152. Epub 1900 01 01.

Results of the citalopram to enhance cognition in Huntington disease trial.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS

Movement disorders : official journal of the Movement Disorder Society.. 2014 March 29 (3):401-5. Epub 12/27/2013.

Does interval between screening and baseline matter in HD cognitive clinical trials?

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Caviness J, Biglan K, Olson B, Paulsen JS

Journal of Huntington's disease.. 2014 3 (2):139-44. Epub 1900 01 01.

A pilot study of virtual visits in Huntington disease.

Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, Dorsey ER, Biglan KM

Journal of Huntington's disease.. 2014 3 (2):189-95. Epub 1900 01 01.

Natural history of Huntington disease.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I,

JAMA neurology.. 2013 December 70 (12):1520-30. Epub 1900 01 01.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I,

JAMA neurology.. 2013 November 70 (11):1382-8. Epub 1900 01 01.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Movement disorders : official journal of the Movement Disorder Society.. 2013 November 28 (13):1823-31. Epub 09/30/2013.

Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism.

McGarry A, Biglan K

Parkinsonism & related disorders.. 2013 June 19 (6):643-4. Epub 04/02/2013.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I

Neurology.. 2013 May 2880 (22):2022-7. Epub 04/26/2013.

Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

Dorsey ER, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, Beck CA, Rajan B, Seidmann A, Biglan KM

JAMA neurology.. 2013 May 70 (5):565-70. Epub 1900 01 01.

Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.

Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM

Parkinsonism & related disorders.. 2013 February 19 (2):218-21. Epub 10/25/2012.

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

JAMA neurology.. 2013 January 70 (1):25-33. Epub 1900 01 01.

Refining the diagnosis of Huntington disease: the PREDICT-HD study.

Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS,

Frontiers in aging neuroscience.. 2013 5 :12. Epub 04/02/2013.

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study.

Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I

Journal of Huntington's disease.. 2013 2 (4):509-15. Epub 1900 01 01.

8-OHdG: its (limited) potential as a biomarker for Huntington's disease.

Killoran A, Biglan KM

Biomarkers in medicine.. 2012 December 6 (6):777-80. Epub 1900 01 01.

Willingness of Parkinson's disease patients to participate in research using internet-based technology.

Shprecher D, Noyes K, Biglan K, Wang D, Dorsey ER, Kurlan R, Adams MJ

Telemedicine journal and e-health : the official journal of the American Telemedicine Association.. 2012 November 18 (9):684-7. Epub 09/06/2012.

Development of the Huntington disease work function scale.

Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS,

Journal of occupational and environmental medicine. 2012 October 54 (10):1300-8. Epub 1900 01 01.

Telemedicine in Leading US Neurology Departments.

George BP, Scoglio NJ, Reminick JI, Rajan B, Beck CA, Seidmann A, Biglan KM, Dorsey ER

The Neurohospitalist.. 2012 October 2 (4):123-8. Epub 1900 01 01.

Web-based clinical assessments for Parkinson's disease: reliable and feasible.

Grana MJ, Bull MT, Venkataraman V, Dorsey ER, Biglan KM

Movement disorders : official journal of the Movement Disorder Society.. 2012 September 1527 (11):1466. Epub 09/18/2012.

Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease.

Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS,

Neuropsychology.. 2012 September 26 (5):664-9. Epub 07/30/2012.

8OHdG as a marker for Huntington disease progression.

Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS,

Neurobiology of disease.. 2012 June 46 (3):625-34. Epub 03/05/2012.

Cognitive domains that predict time to diagnosis in prodromal Huntington disease.

Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS,

Journal of neurology, neurosurgery, and psychiatry.. 2012 June 83 (6):612-9. Epub 03/26/2012.

Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Unschuld PG, Joel SE, Liu X, Shanahan M, Margolis RL, Biglan KM, Bassett SS, Schretlen DJ, Redgrave GW, van Zijl PC, Pekar JJ, Ross CA

Neuroscience letters.. 2012 April 18514 (2):204-9. Epub 03/07/2012.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS, , Landwehrmeyer GB, , Myers RH, , Macdonald ME, Gusella JF,

Neurology.. 2012 March 678 (10):690-5. Epub 02/08/2012.

Therapeutics in Huntington's Disease.

Killoran A, Biglan KM

Current treatment options in neurology.. 2012 February 8 Epub 02/08/2012.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K

Journal of Huntington's disease.. 2012 1 (1):65-9. Epub 1900 01 01.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.

Dorsey R, Biglan K, Eberly S, Auinger P, Brocht A, Umeh CC, Oakes D, Clarence-Smith K, Marshall F, Shoulson I, Frank S

PLoS currents.. 2011 November 133 :RRN1283. Epub 11/13/2011.

Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease.

Carlozzi NE, Stout JC, Mills JA, Duff K, Beglinger LJ, Aylward EH, Whitlock KB, Solomon AC, Queller S, Langbehn DR, Johnson SA, Paulsen JS,

The Clinical neuropsychologist.. 2011 July 25 (5):757-77. Epub 1900 01 01.

Assessment of motor symptoms and functional impact in prodromal and early huntington disease.

Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, Guttman M, Ho AK, Kennard C, Kupchak P, Landwehrmeyer GB, Michell A, Paulsen JS, Reilmann R, van Kammen DP, Warner JH, Evans K

PLoS currents.. 2011 June 142 :RRN1244. Epub 06/14/2011.

Group patient visits for Parkinson disease: a randomized feasibility trial.

Dorsey ER, Deuel LM, Beck CA, Gardiner IF, Scoglio NJ, Scott JC, Marshall FJ, Biglan KM

Neurology.. 2011 May 376 (18):1542-7. Epub 04/27/2011.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE,

Movement disorders : official journal of the Movement Disorder Society.. 2011 March 26 (4):608-13. Epub 02/01/2011.

Co-existence of Parkinson's disease and progressive supranuclear palsy: case report and a review of the literature.

Abhinav K, Marsh L, Crain B, Reich SG, Biglan K

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.. 2011 February 32 (1):159-63. Epub 08/25/2010.

Neurocognitive signs in prodromal Huntington disease.

Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH

Neuropsychology.. 2011 January 25 (1):1-14. Epub 1900 01 01.

Tapping in Huntington disease: a path forward to preventive therapies?

Biglan KM

Neurology.. 2010 December 1475 (24):2142-3. Epub 11/10/2010.

Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.

Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersén A,

Neurobiology of disease.. 2010 December 40 (3):531-43. Epub 08/02/2010.

Cerebral cortex structure in prodromal Huntington disease.

Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS,

Neurobiology of disease.. 2010 December 40 (3):544-54. Epub 08/02/2010.

Challenges assessing clinical endpoints in early Huntington disease.

Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, van Kammen DP,

Movement disorders : official journal of the Movement Disorder Society.. 2010 November 1525 (15):2595-603. Epub 1900 01 01.

Reply: An exploration of the burden experienced by spousal caregivers of individuals with Parkinson's disease.

Deuel LM, Chesire AM, Eason S, Como PG, Biglan KM

Movement disorders : official journal of the Movement Disorder Society.. 2010 October 1525 (13):2254-5. Epub 1900 01 01.

A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups.

Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM

Movement disorders : official journal of the Movement Disorder Society.. 2010 October 1525 (13):2128-35. Epub 1900 01 01.

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study.

Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS,

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.. 2010 September 153B (6):1150-9. Epub 1900 01 01.

Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease.

Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, Miller D, Reminick JI, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Biglan KM

Movement disorders : official journal of the Movement Disorder Society.. 2010 August 1525 (11):1652-9. Epub 1900 01 01.

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.

Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS,

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.. 2010 July 153B (5):1081-93. Epub 1900 01 01.

CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Langbehn DR, Hayden MR, Paulsen JS,

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.. 2010 March 5153B (2):397-408. Epub 1900 01 01.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2009 December 1524 (16):2370-8. Epub 1900 01 01.

Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS,

Movement disorders : official journal of the Movement Disorder Society.. 2009 September 1524 (12):1763-72. Epub 1900 01 01.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM,

Archives of neurology.. 2009 September 66 (9):1099-104. Epub 07/13/2009.

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I,

Neurology.. 2009 August 473 (5):385-92. Epub 1900 01 01.

Telemedicine for the care of nursing home residents with Parkinson's disease.

Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Dorsey ER

Movement disorders : official journal of the Movement Disorder Society.. 2009 May 1524 (7):1073-6. Epub 1900 01 01.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Archives of neurology.. 2009 May 66 (5):563-70. Epub 1900 01 01.

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Marsh L, Biglan K, Gerstenhaber M, Williams JR

Movement disorders : official journal of the Movement Disorder Society.. 2009 January 3024 (2):277-82. Epub 1900 01 01.

Detection of Huntington's disease decades before diagnosis: the Predict-HD study.

Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M,

Journal of neurology, neurosurgery, and psychiatry.. 2008 August 79 (8):874-80. Epub 12/20/2007.

The relationship between CAG repeat length and clinical progression in Huntington's disease.

Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP

Movement disorders : official journal of the Movement Disorder Society.. 2008 July 1523 (9):1223-7. Epub 1900 01 01.

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

Biglan KM, Holloway RG, McDermott MP, Richard IH,

Neurology.. 2007 July 1069 (2):187-95. Epub 1900 01 01.

Long-term fetal cell transplant in Huntington disease: stayin' alive.

Frank S, Biglan K

Neurology.. 2007 June 1268 (24):2055-6. Epub 1900 01 01.

Juvenile-onset huntington disease: a matter of perspective.

Biglan K, Shoulson I

Archives of neurology.. 2007 June 64 (6):783-4. Epub 1900 01 01.

Neuroprotection in Parkinson's disease: an elusive goal.

Biglan KM, Ravina B

Seminars in neurology.. 2007 April 27 (2):106-12. Epub 1900 01 01.

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM

Neurology.. 2007 January 3068 (5):384-6. Epub 11/02/2006.

The eyes as a window into disease prevention.

Biglan KM, Halmagyi M

Neurology.. 2006 August 867 (3):376-7. Epub 1900 01 01.

Rasagiline improves quality of life in patients with early Parkinson's disease.

Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I,

Movement disorders : official journal of the Movement Disorder Society.. 2006 May 21 (5):616-23. Epub 1900 01 01.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A,

Archives of neurology.. 2004 July 61 (7):1044-53. Epub 1900 01 01.

Surrogate endpoints in Parkinson's disease research.

Biglan KM, Holloway RG

Current neurology and neuroscience reports.. 2003 July 3 (4):314-20. Epub 1900 01 01.

Restless legs syndrome and drug-induced akathisia in headache patients.

Young WB, Piovesan EJ, Biglan KM

CNS spectrums.. 2003 June 8 (6):450-6. Epub 1900 01 01.

A review of pramipexole and its clinical utility in Parkinson's disease.

Biglan KM, Holloway RG

Expert opinion on pharmacotherapy.. 2002 February 3 (2):197-210. Epub 1900 01 01.

Initial treatment of early Parkinson's disease: a review of recent, randomized controlled trials.

Biglan K, Holloway RG

Current neurology and neuroscience reports.. 2001 July 1 (4):329-36. Epub 1900 01 01.